Sai - Tech Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 20-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 20-12-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 37.77%
(FY 2021)
- Profit -70.81%
(FY 2021)
- Ebitda -70.49%
(FY 2021)
- Net Worth 157.65%
(FY 2021)
- Total Assets 43.14%
(FY 2021)
About Sai - Tech Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajan Thakur and Savita Thakur serve as directors at the Company.
- CIN/LLPIN
U24100MH2015PTC266811
- Company No.
266811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 2015
- Date of AGM
25 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sai - Tech Pharmaceuticals Private Limited offer?
Sai - Tech Pharmaceuticals Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Ketones, Pharma Ingredients & Raw Materials, API Intermediate.
Who are the key members and board of directors at Sai - Tech Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajan Thakur  | Director | 24-Jul-2015 | Current |
| Savita Thakur | Director | 24-Jul-2015 | Current |
Financial Performance of Sai - Tech Pharmaceuticals.
Sai - Tech Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 37.77% increase. The company also saw a substantial fall in profitability, with a 70.81% decrease in profit. The company's net worth Soared by an impressive increase of 157.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sai - Tech Pharmaceuticals?
In 2021, Sai - Tech Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sanika Chemicals Private LimitedActive 26 years 1 monthRajan Thakur and Savita Thakur are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sai - Tech Pharmaceuticals?
Sai - Tech Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sai - Tech Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai - Tech Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
